Keep our Jobs after Sale?

Discussion in 'Tesaro' started by anonymous, Jan 17, 2018 at 11:46 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Who thinks we will keep our jobs after the sale?
     

  2. anonymous

    anonymous Guest

    depends on how good you are.
     
  3. anonymous

    anonymous Guest

    If you are flexible selling Varubi IV as an alternative fuel source, soybean oil, you will be ok.
     
  4. anonymous

    anonymous Guest

    Did I miss the buyout memo? I’d worry about us getting bought out at a price making it worthwhile...let alone keeping your job. Not a lot to get excited about these days and the future doesn’t look all that great. Oh I forgot...the 4th to market PD1 will save us.
     
  5. anonymous

    anonymous Guest

    Haha, interesting the reactions didn't show up in clinicals. I am hearing combination of screening, pre-meds and/or slowing infusion has solved the issues.
     
  6. anonymous

    anonymous Guest

    Should have had that warning from the launch. We still have an advantage over Emend with our dosage form not requiring IV fluids which is huge right now and less drug interactions, and when Cinvanti launches, they use soybean oil too.
     
  7. anonymous

    anonymous Guest

    Why not bundle Varubi IV with EpiPens?
     
  8. anonymous

    anonymous Guest

    Sanofi snooping around the office again?